Freezing of Gait for Parkinson's Disease

MA
SA
Overseen BySommer Amundsen-Huffmaster, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Minnesota
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to explore the causes and signs of freezing of gait (FOG) in people with Parkinson's disease (PD). The researchers will use a Medtronic Percept™ deep brain stimulation system to examine brain activity in individuals with Parkinson's, both with and without FOG, through various movement tasks. Participants can join one or more of the three experiments, which involve tasks like starting to walk, navigating a course, or moving wrists and feet quickly. Suitable candidates for the trial include those with Parkinson's who can walk without a cane for at least 50 meters and have the Medtronic Percept device implanted. As an unphased trial, this study offers a unique opportunity to contribute to understanding Parkinson's disease and potentially improve future treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this device is safe for use in Parkinson's disease patients?

Research has shown that the Medtronic Percept™ deep brain stimulation (DBS) system is safe for people. The FDA has approved it, indicating it passed strict safety tests for treating Parkinson's disease. Studies have found that patients tolerate this device well, with no new safety issues compared to other DBS systems.

The device is also MR Conditional, meaning it can be safely used during MRI scans if certain guidelines are followed. This ensures patients can still undergo important scans when needed. Overall, the Percept™ DBS system is considered safe for people with Parkinson's disease.12345

Why are researchers excited about this trial?

Researchers are excited about the Medtronic Percept™ deep brain stimulation (DBS) system because it offers a unique approach to managing symptoms of Parkinson's disease, especially freezing of gait (FOG). Unlike traditional treatments like medications that primarily address dopamine levels, this DBS system directly targets specific brain areas involved in motor control. The Percept™ system is designed to deliver personalized stimulation, which could lead to more precise symptom management and potentially improve mobility for those with Parkinson’s disease. This tailored approach is what makes it stand out from current options.

What evidence suggests that the Medtronic Percept™ DBS system is effective for freezing of gait in Parkinson's disease?

Research has shown that the Medtronic Percept deep brain stimulation (DBS) system effectively manages Parkinson's disease symptoms. In this trial, participants with Parkinson's disease will receive the Percept DBS system, with one group experiencing freezing of gait (FOG) and another group without FOG. Studies have found that this system can safely and effectively reduce symptoms like FOG, a sudden and temporary inability to move that often affects people with Parkinson's. One study demonstrated that using the Percept DBS system improved walking by focusing on specific brain signals related to movement. The FDA has already approved this system, and it has been successfully used in people with Parkinson's disease.16789

Are You a Good Fit for This Trial?

This trial is for people aged 21-75 with idiopathic Parkinson's Disease who can walk without help and have a Medtronic Percept TM Device implanted. It's not for those using assistive devices or anyone outside the age range.

Inclusion Criteria

I have an implanted Medtronic Percept TM device.
My neurostimulator has been active for at least 3 months.
I belong to a group that is often overlooked or marginalized.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Experiment 1

Comparison of LFPs during gait initiation with and without a cue in people with and without FOG

4 weeks
Multiple sessions (in-person)

Experiment 2

Comparison of LFPs during successful movement transitions vs. freezing-events during a FOG provocation course in people with FOG

4 weeks
Multiple sessions (in-person)

Experiment 3

Comparison of LFPs during rapid alternating movements of the wrist and/or foot in people with and without FOG

4 weeks
Multiple sessions (in-person)

Follow-up

Participants are monitored for safety and effectiveness after experiments

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Medtronic Percept™ deep brain stimulation system
Trial Overview The study tests how brain signals during movement differ in Parkinson's patients with and without freezing of gait (FOG). Participants will undergo experiments comparing brain activity in various scenarios, both on and off their usual PD medications or deep brain stimulation.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Parkinson's disease without freezing of gaitExperimental Treatment2 Interventions
Group II: Parkinson's disease with freezing of gaitExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Minnesota

Lead Sponsor

Trials
1,459
Recruited
1,623,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+

Citations

NCT06848205 | Percept Transitions in FOG and PDThe purpose of this research is to examine the possible causes and signs of freezing of gait (FOG) secondary to Parkinson's disease (PD).
Long-Term Personalized Adaptive Deep Brain Stimulation ...This nonrandomized clinical trial evaluates the use of adaptive deep brain stimulation in Parkinson disease.
Beta Burst-Driven Adaptive Deep Brain Stimulation ...The goal of the current study was to investigate the feasibility, safety, and tolerability of beta burst-driven adaptive DBS (aDBS) for FOG in PD.
P960009/S478 Summary of Safety and Effectiveness (SSED)The study was a prospective, multicenter, single-arm, aDBS treatment mode blind, randomized crossover trial in subjects with Parkinson's Disease and DBS leads.
Beta burst-driven adaptive deep brain stimulation for gait ...The goal of the study was to investigate the feasibility, safety and tolerability of beta burst-driven adaptive deep brain stimulation for gait impairment and ...
Percept PC - DBS for Parkinson's DiseaseMedtronic DBS systems are MR Conditional and safe in the MR environment as long as certain conditions are met.
Deep Brain Stimulation - Indications, Safety, and WarningsMedtronic DBS systems are MR Conditional which means they are marked to indicate they are safe in the MR environment as long as certain conditions are met.
Percept™ PC NeurostimulatorThe Percept™ PC is a recharge free neurostimulator with sensing, directionality, and advanced programming capabilities for deep brain stimulation (DBS).
Device profile of the percept PC deep brain stimulation ...There are no new safety concerns regarding the Percept™ PC DBS device, which carries the same contraindications, warnings and precautions as other DBS devices ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security